May 16, 2023
| Dharam J. Kumbhani, MD, SM, FACC
Clinical Trial
The goal of the ODYSSEY OUTCOMES trial was to compare the safety and efficacy of alirocumab compared with placebo among patients with recent acute coronary syndrome (ACS) already on intensive or maximum-tolerated statin therapy.
Clinical Topics: Acute Coronary Syndromes, Cardiac Surgery, Cardiovascular Care Team, Diabetes and Cardiometabolic Disease, Dyslipidemia, Geriatric Cardiology, Invasive Cardiovascular Angiography and Intervention, Prevention, Pulmonary Hypertension and Venous Thromboembolism, Vascular Medicine, Atherosclerotic Disease (CAD/PAD), Cardiac Surgery and Arrhythmias, Lipid Metabolism, Nonstatins, Novel Agents, Statins, Interventions and ACS, Interventions and Vascular Medicine
Keywords: ACC22, ACC Annual Scientific Session, ACC19, AHA18, AHA Annual Scientific Sessions, ACC18, Acute Coronary Syndrome, Antibodies, Monoclonal, Angina, Unstable, Apolipoproteins, Apolipoproteins A, Apolipoproteins B, Brain Ischemia, Cholesterol, HDL, Cholesterol, LDL, Coronary Disease, Cost-Benefit Analysis, Diabetes Mellitus, Dyslipidemias, Geriatrics, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Lipids, Myocardial Infarction, Myocardial Revascularization, Peripheral Arterial Disease, Secondary Prevention, Stroke, Treatment Outcome, Venous Thromboembolism